EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Cynthia L Palmer, Britton Boras, Bernadette Pascual, Na Li, Danan Li, Scott Garza, Nanni Huser, Jing Tang Yuan, Julie A Cianfrogna, Tae Sung, Elizabeth McMillan, Na Wei und 40 weitere

Cancer Cell · 2025-03 · 43 (3) · 464-481.e14

DOI: 10.1016/j.ccell.2025.02.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025-03. Verfasst von Cynthia L Palmer und 51 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, CA 92121, USA. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Protein Kinase Inhibitors, Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Industrial Macromolecular Crystallography Association Collaborative Access Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CDK4/6 inhibitors have revolutionized treatment of hormone receptor positive (HR+), HER2 non-amplified (HER2-) breast cancer. Yet, all "dual" CDK4/6 inhibitors show common dose-limiting hematologic toxicities, foremost neutropenia. This poses challenges to provide these agents at concentrations necessary to extinguish cell cycling in tumors. HR+ breast cancer cells are highly dependent on CDK4 but not CDK6. By contrast, CDK4 is dispensable for human bone marrow derived cells, due to the primary and compensatory role of CDK6 in hematopoiesis. This prompted us to develop atirmociclib (PF-07220060), a next-generation CDK4 selective inhibitor. Atirmociclib's impact on circulating neutrophils was reduced, in proportion with its increase in CDK4 versus CDK6 selectivity. Realized dose intensification led to greater CDK4 inhibition and deeper anti-tumor responses, pointing to CDK4 target coverage as a limiting factor of CDK4/6 inhibitor efficacy. We also highlight combinatorial agents that may counter acquired resistance to CDK4 selective inhibition and widen its clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Protein Kinase InhibitorsBreast NeoplasmsAntineoplastic AgentsHumansAnimalsFemaleMiceCyclin-Dependent Kinase 6Xenograft Model Antitumor AssaysCell Line, Tumor

Stichwörter der Autor:innen

CDK4CDK6PF-07220060atirmociclibbreast cancercell cyclecell cycle inhibitorcyclin D1cyclin-dependent kinaseneutropenia

Substanzen

Cyclin-Dependent Kinase 4CDK4 protein, humanProtein Kinase InhibitorsCyclin-Dependent Kinase 6Antineoplastic AgentsCDK6 protein, human

Autor:innen und Institutionen

  • Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, CA 92121, USA.
  • Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, CA 92121, USA. Electronic address: lars.anders@pfizer.com.

Förderung

  • Industrial Macromolecular Crystallography Association Collaborative Access Team

Zitieren

APA

Palmer, C. L., Boras, B., Pascual, B., Li, N., Li, D., Garza, S., Huser, N., Yuan, J. T., Cianfrogna, J. A., Sung, T., McMillan, E., Wei, N., Carmody, J., Kang, A. N., Darensburg, S., Dodd, T., Oakley, J. V., Solowiej, J., Nguyen, L., …, & Anders, L. (2025). CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell, 43(3), 464-481.e14. https://doi.org/10.1016/j.ccell.2025.02.006

Vancouver

Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell. 2025;43(3):464-481.e14. doi:10.1016/j.ccell.2025.02.006

BibTeX
@article{Palmer2025,
  author = {Palmer, Cynthia L and Boras, Britton and Pascual, Bernadette and Li, Na and Li, Danan and Garza, Scott and Huser, Nanni and Yuan, Jing Tang and Cianfrogna, Julie A and Sung, Tae and McMillan, Elizabeth and Wei, Na and Carmody, Jason and Kang, Aubrey Nayeon and Darensburg, Seth and Dodd, Taran and Oakley, James V and Solowiej, James and Nguyen, Lisa and Orr, Suvi T M and Chen, Ping and Johnson, Eric and Yu, Xiu and Diehl, Wade C and Gallego, Gary M and Jalaie, Mehran and Ferre, Rose Ann and Cho-Schultz, Sujin and Shen, Hong and Deal, Judith G and Zhang, Qin and Baffi, Timothy R and Xu, Meirong and Roh, Whijae and Lapira-Miller, Jennifer and Goudeau, Jerome and Yu, Yanke and Gupta, Rajat and Kim, Kimberly and Dann, Stephen G and Kan, Zhengyan and Kath, John C and Nair, Sajiv K and Miller, Nichol and Murray, Brion W and Nager, Andrew R and Quinlan, Casey and Petroski, Matthew D and Zhang, Cathy and Sacaan, Aida and VanArsdale, Todd and Anders, Lars},
  title = {CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {3},
  pages = {464--481.e14},
  doi = {10.1016/j.ccell.2025.02.006}
}
Kostenlos starten →